Acute cystitis in men- a nationwide study from primary care: antibiotic prescriptions, risk factors, and complications.

IF 2.5 Q2 PRIMARY HEALTH CARE
BJGP Open Pub Date : 2024-07-29 Print Date: 2024-07-01 DOI:10.3399/BJGPO.2023.0207
Håkon Sætre, Marius Skow, Ingvild Vik, Sigurd Høye, Louise Emilsson
{"title":"Acute cystitis in men- a nationwide study from primary care: antibiotic prescriptions, risk factors, and complications.","authors":"Håkon Sætre, Marius Skow, Ingvild Vik, Sigurd Høye, Louise Emilsson","doi":"10.3399/BJGPO.2023.0207","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Research on acute cystitis in men is scarce and treatment guidelines differ between countries. Improved antibiotic stewardship is needed.</p><p><strong>Aim: </strong>To analyse antibiotic prescriptions and outcomes of Norwegian men diagnosed with cystitis in primary care.</p><p><strong>Design & setting: </strong>A nationwide retrospective study was undertaken in primary care in Norway.</p><p><strong>Method: </strong>We identified all episodes of acute cystitis in men diagnosed in Norwegian primary care during 2012-2019. Choice of antibiotic (from the Norwegian Prescription Database), treatment failure, re-prescription, and complications were stratified by age, calendar year, and risk factors. We used logistic regression to explore predefined risk factors (diabetes, prostate cancer, benign prostate hyperplasia [BPH], urinary retention, and any cancer) with complications (pyelonephritis, prostatitis, and hospitalisation) and re-prescriptions. Linear regression was used to explore time trends.</p><p><strong>Results: </strong>In total, 108 994 individuals contributed 148 635 episodes. Narrow-spectrum antibiotics were first-choice treatment in 71.0% of the episodes (52.5% of all prescriptions were pivmecillinam). More than 75% of the episodes with narrow-spectrum versus 82.2% of broad-spectrum treatment did not lead to any re-prescription or complication. Complications occurred in 1.8% of all episodes (0.5% prostatitis, 0.7% pyelonephritis, and 0.7% hospitalisation). BPH was associated with increased risk of complications and re-prescription. Diabetes was associated with a lower risk of re-prescriptions. Prostate cancer and urinary retention were associated with a lower risk of both complications and re-prescriptions.</p><p><strong>Conclusion: </strong>Our results support narrow-spectrum antibiotics as first-line treatment. Risk factor analyses warrants further investigation.</p>","PeriodicalId":36541,"journal":{"name":"BJGP Open","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300979/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJGP Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3399/BJGPO.2023.0207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Research on acute cystitis in men is scarce and treatment guidelines differ between countries. Improved antibiotic stewardship is needed.

Aim: To analyse antibiotic prescriptions and outcomes of Norwegian men diagnosed with cystitis in primary care.

Design & setting: A nationwide retrospective study was undertaken in primary care in Norway.

Method: We identified all episodes of acute cystitis in men diagnosed in Norwegian primary care during 2012-2019. Choice of antibiotic (from the Norwegian Prescription Database), treatment failure, re-prescription, and complications were stratified by age, calendar year, and risk factors. We used logistic regression to explore predefined risk factors (diabetes, prostate cancer, benign prostate hyperplasia [BPH], urinary retention, and any cancer) with complications (pyelonephritis, prostatitis, and hospitalisation) and re-prescriptions. Linear regression was used to explore time trends.

Results: In total, 108 994 individuals contributed 148 635 episodes. Narrow-spectrum antibiotics were first-choice treatment in 71.0% of the episodes (52.5% of all prescriptions were pivmecillinam). More than 75% of the episodes with narrow-spectrum versus 82.2% of broad-spectrum treatment did not lead to any re-prescription or complication. Complications occurred in 1.8% of all episodes (0.5% prostatitis, 0.7% pyelonephritis, and 0.7% hospitalisation). BPH was associated with increased risk of complications and re-prescription. Diabetes was associated with a lower risk of re-prescriptions. Prostate cancer and urinary retention were associated with a lower risk of both complications and re-prescriptions.

Conclusion: Our results support narrow-spectrum antibiotics as first-line treatment. Risk factor analyses warrants further investigation.

男性急性膀胱炎--一项来自基层医疗机构的全国性研究:抗生素处方、风险因素和并发症。
背景:有关男性急性膀胱炎的研究很少,各国的治疗指南也不尽相同。目的:分析在初级医疗机构诊断为膀胱炎的挪威男性患者的抗生素处方和治疗结果:我们确定了2012-2019年期间在挪威初级医疗机构确诊的所有男性急性膀胱炎病例。根据年龄、日历年和风险因素对抗生素的选择(来自挪威处方数据库)、治疗失败、重新处方和并发症进行分层:我们采用逻辑回归法探讨了预定义风险因素(糖尿病、前列腺癌、良性前列腺增生症(BPH)、尿潴留和任何癌症)与并发症(肾盂肾炎、前列腺炎和住院治疗)和重新处方的关系。采用线性回归分析时间趋势:总共有 108,994 人使用了 148,635 次抗生素。71%的病例首选窄谱抗生素治疗(53%的处方为匹维西林)。在使用窄谱抗生素治疗的病例中,超过 75% 的病例与 82% 使用广谱抗生素治疗的病例相比,没有发生任何重新处方或并发症。并发症发生率为 1.8%(前列腺炎 0.5%、肾盂肾炎 0.7% 和住院治疗 0.7%)。前列腺增生症与并发症和重新处方的风险增加有关。糖尿病与较低的再处方风险有关,前列腺癌和尿潴留与较低的并发症和再处方风险有关:结论:我们的研究结果支持将窄谱抗生素作为一线治疗药物。风险因素分析值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BJGP Open
BJGP Open Medicine-Family Practice
CiteScore
5.00
自引率
0.00%
发文量
181
审稿时长
22 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信